Immunofoco is a clinical-stage biotech company, devoted to bringing revolutionary immune cell drugs to patients with solid tumors. The operation started in September 2020, with the founding members combined the mavens from the industry, academia, business, and medical professions, and the executive committees had their hands on all the critical activities in advancing the regulatory approval of the first CAR-T drug in China.

We draw our attention to the clinical barriers of the solid tumors and have adopted firstly the strategy of “curing the solid tumors by treating them as hematologic malignancies”. And we have established the Peri Cruiser®, SNR, T-Booster and other innovative platforms to further reduce the toxicity risks, improve the ability to resist tumor heterogeneity, and promote expansion and tumor infiltration of CAR-T cells.

Driven by the clinical outcomes, our company maintains an extensive spectrum of product pipeline. Notably, our IMC002 (CLDN18.2 CAR-T) product obtained ODD from the U.S. FDA in July 2022, and its IND application has been approved in both the U.S. and China in April 2023. Similarly, our IMC001 (EpCAM CAR-T) product obtained ODD from the U.S. FDA in August 2023, with its IND application has been approved in both the U.S. and China in February 2024. The IMC008 (SNR CAR-T) product has rapidly moved to the IIT stage and received two ODD approval from the U.S. FDA in August 2023, for the treatment of gastric cancer and pancreatic cancer, respectively.

With the mission of pursuing breakthroughs in solid tumor treatments with immune cell therapies, we are working with internal and external industry talents, to bring survival benefits to patients with solid tumors.